Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stacy R. Lindborg
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Beta
- 2.08
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -54.03
Financials
Revenue
$0.00-100.0%Net Income
$-3.75MEBITDA
$-3.42MFree Cash Flow
$-3.20MEPS (diluted)
$-0.64Shares Outstanding (diluted)
5.95M+4297.2%Operating Expenses
$3.45MCash & Debt
$4.04MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-14.49M | $-6.83 |
| 2024 | $0.00 | $-18.62M | $-21.10 |
| 2023 | $0.00 | $-19.51M | $-28.14 |
| 2022 | $500.0K | $-35.90M | $-65.55 |
| 2021 | $500.0K | $-20.77M | $-748.77 |
| 2020 | $500.0K | $-21.48M | $-131.51 |
| 2019 | $500.0K | $-16.85M | $-151.01 |
| 2018 | $500.0K | $-11.88M | $-132.23 |
| 2017 | $500.0K | $-20.40M | $-532.22 |
| 2016 | $500.0K | $-22.05M | $-2328.26 |
| 2015 | $500.0K | $-22.46M | $-2821.30 |
| 2014 | $500.0K | $-25.49M | $-3780.00 |
| 2013 | $500.0K | $-8.25M | $-2602.17 |
| 2012 | $0.00 | $-26.57M | $-9367.82 |
Valuation
IMNNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·10d ago·Neutral
IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026 LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
IMUNON to Participate in Upcoming Investor Conferences LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…inal Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company's newly designated, non-c…
View source ↗ - Newsseekingalpha.com·60d ago·Positive
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·61d ago·Neutral
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
View source ↗ - Newsglobenewswire.com·73d ago·Neutral
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
View source ↗ - Newsglobenewswire.com·88d ago·Neutral
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Tue, Mar 30(in 4 months)
Consensus estimate $-0.60 per share
Typical surprise +20.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.64 vs $-0.55miss
- Tue, Aug 11$-0.54 vs $-0.87beat
- Tue, May 12$-0.84 vs $-1.22beat
- Tue, Mar 31$-1.29 vs $-1.43beat
- Thu, Nov 13$-1.16 vs $-1.20beat
- Tue, Aug 5$-1.87 vs $-3.09beat
Estimates and results for IMNN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMNN officers and directors.
- Bought
- —
- Sold
- $38k
0 trades
6 trades
- Eylward Susansold
- Eylward Susansold
- Eylward Susansold
- Eylward Susansold
- Eylward Susansold
- Eylward Susansold
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMNN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
